Mucormycosis in COVID-19
Vasantha Kamath, Manimegalai Mathivanan, R B Vinay and 1 more
APIK Journal of Internal Medicine · 2021
doi:10.4103/ajim.ajim_74_21 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Mucormycosis has emerged as a disease of immense importance, especially owing to the surge of cases during the second wave of COVID pandemic. Various factors are being attributed to the sudden burst of cases in our country, such as higher fungal spore counts in tropical climate, uncontrolled diabetes mellitus, prolonged steroid therapy, contamination of oxygen facilities, respiratory equipment, reused face mask, and zinc supplements. The need of the hour is to emphasize on awareness of early warning signs, as the benefits appear to be time sensitive.
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.